http://www.chartsbank.com/PipelineList.aspx
Market analysts estimate that most pharmaceutical firms will need to double the number of new chemical entities they develop to meet Wall Street analysts’ growth expectations. Pharmaceutical-biotechnology alliances will shore up pipelines of pharmaceutical companies, reported by business intelligence firm Bulresearch Inc.
Called the pipeline problem, pharmaceutical companies are partly victims of their industry’s success. Rapid growth of blockbuster products forces each major company to build a stronger pipeline of new blockbusters. Pharmaceutical-biotechnology alliances help solve the pipeline problem that plagues pharmaceutical companies. These partnerships are a new competitive ground for more blockbusters than can be developed internally.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment